LACTEL L-PL (B6002-1) is supplied as a biomedical ester-terminated poly(L-lactide) resin. The designation identifies an L-lactide homopolymer architecture in which the chain terminus is ester-capped rather than present as a free carboxylic acid. This chain-end modification reduces the initial concentration of terminal carboxyl groups available to catalyze hydrolytic degradation and can lower the apparent acidity of the polymer in drug-loaded matrices and implant coatings. The B6002-1 suffix functions as a product-code identifier within the L-PL series; it is not an intrinsic viscosity value, and numerical lot specifications must be read from the certificate of analysis. The material occupies a slow-resorbing segment of the absorbable polyester design space and is typically evaluated for implantable structural components, drug-eluting coatings, microspheres, fibers, and porous scaffolds where semicrystalline L-lactide repeat units, controlled chain-end chemistry, and extended degradation are process-critical. No claim of device-level regulatory clearance is conveyed by the raw material code alone.

What Differentiates an Ester-Terminated Poly(L-lactide) Chain from an Acid-Capped PLLA Grade?

The functional distinction of the B6002-1 grade resides at the polymer chain terminus. In acid-terminated PLLA, each terminal carboxyl group contributes to a local acidic microclimate that accelerates ester cleavage through autocatalysis. The ester-capped architecture replaces the terminal carboxylic acid with a non-acidic ester function, reducing the initial acid number and altering the early-stage hydrolysis profile. Published data on comparable medical-grade PLLA have associated ester capping with reduced early molecular weight loss under humid storage and lower carboxylic acid content in extracted matrix material. However, ester termination does not eliminate hydrolytic degradation; water diffuses through the amorphous regions and cleaves backbone ester linkages regardless of end-group chemistry. The principal difference is the suppression of the autocatalytic contribution, not the removal of hydrolysis. This makes B6002-1 relevant for matrices carrying acid-sensitive active pharmaceutical ingredients or devices where delayed onset of mass loss is specified. Final degradation behavior must be evaluated in the intended geometry because autocatalysis is also influenced by part thickness and diffusion path length. The ester end-group influences chain-end mobility, solution acidity, and degradation-induced chain scission, but it does not fundamentally change the semicrystalline character of the L-lactide repeat unit.

Specification limits for the B6002-1 code are not standalone values; they are read against the lot-specific certificate of analysis and the internal release criteria of the converting facility. Typical parameters recorded for biomedical PLA resins include inherent viscosity in chloroform at 25 °C at a concentration of 0.1 g/dL, residual lactide monomer by gas chromatography, residual solvent by headspace gas chromatography, tin catalyst residue by inductively coupled plasma mass spectrometry, and molecular weight distribution by gel permeation chromatography. The polymer is usually characterized by a glass transition temperature of 55–65 °C and, after annealing, a melting endotherm of 170–180 °C for semicrystalline PLLA, as determined by differential scanning calorimetry per ISO 11357-2:2020. Published multi-lot data for this exact B6002-1 configuration is limited; manufacturers evaluating the material should not substitute these general PLLA ranges for lot-specific acceptance criteria. Viscosity-average molecular weight and inherent viscosity remain the controlling indicators for a given application. An ester-terminated chain with equivalent inherent viscosity will not automatically exhibit the same melt strength or film-forming behavior as an acid-capped analogue because terminal group identity affects chain-session rates during processing and storage. Lot-to-lot variability in inherent viscosity can alter dissolution time, melt viscosity, and fiber draw; users should establish internal control limits against qualified reference lots. Residual monomer content is particularly relevant in biomedical processing because free lactide can migrate in the final device and contribute to extractables. The grade is typically supplied in sealed, moisture-barrier packaging, and the packaging condition is part of the release specification rather than a secondary recommendation.

Processing Boundaries and Moisture Control in Melt Fabrication

Before any melt-processing campaign, moisture removal is the controlling variable. The resin must be dried below a moisture threshold typically specified at 0.025 wt% (250 ppm) to avoid hydrolytic molecular weight loss during extrusion or injection molding. Vacuum drying at 80 °C for 12 h or desiccant drying to a dew point of -40 °C is representative of industrial practice for high-purity PLA, but the B6002-1 lot-specific drying profile should be confirmed. Melt processing of ester-terminated PLLA has been reported on co-rotating twin-screw extruders with length-to-diameter ratios of 25:1 and 40:1, using barrel profiles between 180 °C and 210 °C. When barrel set points exceed 220 °C, residence times above 8 min are associated with measurable molecular weight reduction in PLLA; published data for this specific B6002-1 configuration is limited. Injection molding has been performed with barrel profiles from 170 °C to 200 °C and mold temperatures either below 30 °C for amorphous parts or 100–120 °C for semicrystalline parts requiring in-mold crystallization. Clamp force is set by projected area and runner geometry rather than by polymer grade; for thin-wall components, packing pressure and hold time are the primary grade-dependent parameters. The ester end-cap does not remove the need for moisture control, but it can reduce the severity of viscosity loss when trace moisture is present by limiting terminal carboxyl generation. Residence-time distribution in twin-screw compounding widens at low feed rates and high screw speeds, producing a high-molecular-weight tail and premature degradation of the low-molecular-weight fraction. The B6002-1 chain-end structure does not eliminate this effect, and screw configuration should therefore be matched to the shear sensitivity of the grade.

Solvent-based fabrication routes for B6002-1 are generally bounded by solvent purity, solution concentration, and residual water content rather than by a single universal solubility limit. The resin is dissolved in chlorinated solvents such as dichloromethane or chloroform, with solution concentrations typically between 1 wt% and 10 wt% depending on target viscosity and coating or spinning geometry. Because ester-terminated PLLA has fewer free acid end-groups, the solution may show lower initial acidity during long residence times; however, solvent selection and water content remain critical because dissolved water can still initiate backbone hydrolysis. Filtration through 0.2 µm or 0.45 µm membrane filters is common before coating or electrospinning to remove gel particles and environmental contaminants. For microsphere encapsulation, solvent evaporation or extraction routes using dichloromethane and an aqueous continuous phase require pH adjustment of the aqueous phase; the reduced acid end-group concentration in B6002-1 may narrow the pH shift during hardening when compared with acid-terminated PLLA. Final residual solvent must meet the applicable pharmacopoeial or regulatory limit, such as ICH Q3C residual solvent classes, with the specific limit depending on the solvent and the intended patient exposure. Published data for the B6002-1 configuration in each solvent system is limited, so feasibility trials should include viscosity, cloud point, and residual solvent measurements. In drug-eluting coatings, migration kinetics in the polymer matrix are influenced by free volume, crystallinity, and chain-end polarity; the ester-capped terminus reduces one source of ionic interaction with basic drug substances, but final release behavior must be confirmed by in vitro dissolution testing.

Where the B6002-1 Grade Occupies a Different Design Space Than PLGA Copolymers and DL-Lactide Homopolymers

Compared with a 50:50 PLGA copolymer of equivalent molecular weight, the L-PL repeat unit lacks the glycolide methylene group that increases hydrophilicity and accelerates degradation. The B6002-1 ester-terminated PLLA therefore exhibits slower water uptake, lower copolymer hydrophilicity, and longer in vivo mass loss profiles. High-molecular-weight PLLA devices may retain mass for more than 12 months depending on geometry and implantation site, whereas 50:50 PLGA typically degrades over weeks to months. The semicrystalline L-lactide homopolymer also provides higher tensile modulus after orientation than amorphous DL-lactide or PLGA; however, the crystalline regions of PLLA are less permeable to water and can produce heterogeneous degradation with a hollow core in thick implants. In contrast, acid-terminated PLLA of the same stereoregularity may degrade faster in the early phase because terminal carboxyl groups concentrate in the amorphous phase and increase local chain scission. The ester-terminated architecture therefore shifts the design space toward applications requiring slower and more predictable initial degradation, lower extractable acidity, or compatibility with acid-labile compounds. It is not a substitute for PLGA in fast-resorbing drug delivery systems, nor is it an amorphous DL-lactide grade for low-temperature elastic matrices. Each application must be matched by molecular weight, inherent viscosity, and end-group functionality rather than by polymer family alone.

Storage stability of ester-terminated PLLA is governed by the same hydrolytic sensitivity as other aliphatic polyesters, but the reduced terminal acid content can extend dry-state shelf life when packaging remains sealed. The resin should be stored in a cool, dry environment and kept in moisture-barrier packaging until use. Once the primary container is opened, the material should be transferred to a dry environment or re-dried according to the processor’s qualified procedure. Contact with amine-based additives or strongly alkaline buffer systems may accelerate chain scission and should be avoided unless compatibility has been demonstrated in the final device matrix. For implantable applications, raw material storage conditions should be captured in the device master record because moisture history before processing can affect molecular weight and final degradation kinetics. The ester-capped terminus does not confer unlimited stability; it reduces one degradation accelerator but does not remove the need for controlled handling.

What Supporting Test Data Are Required for ISO 10993 Evaluation of the B6002-1 Grade?

Biomedical evaluation of the B6002-1 grade is not a single checklist; it requires chemical characterization, degradation product analysis, and biological evaluation under a risk-based approach. The polymer can be screened for cytotoxicity per ISO 10993-5:2009 and for degradation products per ISO 10993-13:2010. The final device must be evaluated according to ISO 10993-1:2018, using the device-specific biological endpoints identified in the risk assessment. For implantable applications, tests for sensitization, irritation, systemic toxicity, implantation, and genotoxicity may be warranted depending on tissue-contact duration and patient population. The ester-terminated architecture may change the degradation product profile by reducing acidic oligomer release in early stages; however, the bulk degradation pathway still yields lactic acid as the ultimate degradation product. Therefore, the grade should not be considered inherently compliant with any specific device standard. Resin-level certification may include biocompatibility data for the raw material, but final sterilization, processing aids, packaging, and device geometry can alter the biological response. Sterilization by ethylene oxide or gamma irradiation may introduce changes in molecular weight and acid content; published data for the B6002-1 configuration is limited, so dose-setting with bioburden and post-irradiation viscosity testing is required. No claim of FDA device clearance or CE marking is conveyed by the raw material designation alone. Final device validation under ISO 13485:2016 and applicable regulatory requirements remains the responsibility of the finished-device manufacturer.